Oculis Holding AG (OCS) ニュース

OCULIS HOLDING AG 2024 Annual Meeting
Vote by ?May 28, 2024?.

As a shareholder in OCULIS HOLDING AG, you have the right to vote in an important election that may affect your investment. Don't miss your chance to make your choice.

Control number: ?5143300656873184?

Account number: ?#####783?

Meeting date: ?May 29, 2024?

OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV.

Riad Sherif, M.D., Chief Executive Officer of Oculis, will deliver a company presentation on Wednesday, May 15th at 11:20am PT at the Encore Hotel. A live webcast of the presentation will be available here.

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their Bank of America representative to request meetings. A link to access company presentation, when available, will be posted to Oculis website on the Events & Presentation page under the Investors & Media section.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02, a topical biologic anti-TNFa eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts
Ms. Sylvia Cheung, CFO

http://archive.fast-edgar.com/20240228/A82VH62CZZ2RMZZ222JN2ZYSKFCFZZ223262/

Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences:

Stifel Biotech Executive Summit
Format: Fireside chat
Presenter: Riad Sherif, MD, Chief Executive Officer
Presentation date and time: February 7, 2024 at 7:30 am MT (Mountain Time)
Location: Pendry Park City, Park City, Utah, USA

BioCapital Europe 2024
Format: Company presentation
Presenter: Sylvia Cheung, Chief Financial Officer
Presentation date and time: February 8, 2024 at 11:40 am CET (Central European Time)
Location: Hotel Sofitel Legend The Grand Amsterdam, Amsterdam, Netherlands

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it will host an in-person R&D Day in Midtown, New York City, on Wednesday, February 28, 2024 from 9:00 AM to 11:00 AM ET. Please click here to attend the event either in-person or virtually. Location details for in-person attendance will be provided upon registration.

The event will showcase two of Oculis’ clinical programs:

OCS-01, a high concentration dexamethasone eye drop formulation developed with the proprietary OPTIREACH® technology to reach the retina, in Diabetic Macular Edema (DME): presentations will include an update on the OCS-01 development programs and a discussion of how OCS-01 could transform the current treatment paradigm by addressing the pre-invasive patient segment with an early intervention, and the segment of patients with inadequate response to current standard of care, from:

David Boyer, M.D. (Keck School of Medicine, University of Southern California, and Retina Vitreous Associates Medical Group)
Arshad M. Khanani, M.D., M.A. FASRS (Reno School of Medicine, University of Nevada, and Sierra Eye Associates)
Ramin Tadayoni, M.D., Ph.D. (Université Paris Cité, Lariboisière & Rothschild Foundation Hospitals, Paris, President of EURETINA)
Elizabeth Yeu, M.D. (Eastern Virginia Medical School, Virginia Eye Consultants, and President of ASCRS)
OCS-02, a TNFa inhibitor licaminlimab eye drop formulation developed with a proprietary antibody fragment technology to treat ocular inflammation, in Dry Eye Disease (DED): presentations will cover the unmet medical need, TNF inhibition mechanism of action to manage ocular inflammation, the potential for a precision medicine approach in DED, and an overview of the licaminlimab (OCS-02) RELIEF trial program, from:

Christophe Baudouin, M.D. Ph.D. (Quinze-Vingts National Ophthalmology Hospital, Paris)
Eric Donnenfeld, M.D. (New York University)
Anat Galor, M.D., M.S.P.H. (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami)
George Ousler, M.S. (Ora, Inc.)
Victor Perez, M.D. (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami)
The topic discussions will be moderated by Pravin Dugel, M.D. (Director, Oculis’ Board) and Riad Sherif, M.D. (Chief Executive Officer, Oculis).

In addition, management will provide a brief 2023 review and business outlook for 2024. Live question and answer sessions will be conducted during the event.

Initiation of the second Phase 3 OPTIMIZE-2 trial with OCS-01 once daily eye drop, follows the recently reported positive OPTIMIZE-1 trial results
OPTIMIZE-2 topline readout expected before end of 2024 to support NDA submission
OCS-01 is also being evaluated as potentially the first topical eye drop treatment for Diabetic Macular Edema (DME) in the DIAMOND program and for the treatment of Cystoid Macular Edema (CME) in the LEOPARD trial
ZUG, Switzerland, and BOSTON, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced First Patient First Visit (FPFV) in OCS-01 Phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the Phase 3 OPTIMIZE-2 trial is intended to support the Company’s NDA submission to the Food and Drug Administration (FDA). If approved, OCS-01 has the potential to be the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

The OPTIMIZE-2 (Once-daily Post-ocular surgery Treatment for InflaMmation and paIn to minimiZE drops) is a multi-center, randomized, double-masked, vehicle-controlled Phase 3 trial evaluating OCS-01 for the treatment of inflammation and pain following cataract surgery. Similar to the OPTIMIZE-1 trial, patients in the second Phase 3 OPTIMIZE-2 trial will be treated with once-daily OCS-01 post-cataract surgery versus vehicle for 2 weeks. Primary endpoints are the absence of anterior chamber cells (inflammation) on Day 15 and absence of pain on Day 4. The OPTIMIZE-2 trial follows the positive topline results from the OPTIMIZE-1 trial showing that OCS-01 increased the percentage of patients who were inflammation free at Day 15 and had zero pain at Day 4 vs. vehicle with statistical significance (p